Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
Rola Ghasoub, Clinical Pharmacist at Hamad Medical Corporation, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, published in Karger Oncology, adding:
“Publication Alert!
Excited to share that our manuscript has been accepted for publication in Karger Oncology!
‘Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar’
This work represents 13 years of real-world data from our national cancer center in Qatar, capturing the full journey of 87 adults diagnosed with APL, one of the most curable, yet also among the most urgent, leukemias to recognize and treat.
Key findings:
- Contemporary ATRA–ATO regimens delivered high complete remission rates and durable long-term survival
- Early mortality, principally from intracranial hemorrhage, remains the dominant barrier to cure, even in a young, low-comorbidity population
- Excluding patients presenting with ICH, 5-year overall survival reached 87.6%, closely matching top clinical trial benchmarks
This study highlights that the real-world survival gap in APL is primarily observed in the high-risk subgroup at diagnosis, underscoring the critical importance of rapid recognition, immediate initiation of empiric ATRA, and optimized emergency care pathways.
I am grateful to have contributed to this work with Prof. Honar Cherif and the exceptional team at the National Center for Cancer Care and Research.”
Title: Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar
Authors: Rola Ghasoub, Hesham Elsabah, Anas Hamad, Nabeel Mohammad Qasem, Hawra Shwylia, Feryal Ibrahim, Halima Elomri, Rajvir Singh, Shehab Fareed, Abdulrahman F. Al-Mashdali, Anil Ellahie, Honar Cherif
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 15, 2026, 19:30José Luis Neyro: E4 and DRSP Reduce Hirsutism While Showing Comparable Effects on Thrombin Generation
-
Aug 15, 2026, 19:27Mahmoud Akraym: Don’t Choose Anticoagulation as the Immediate Treatment for Unstable AF
-
Aug 15, 2026, 19:25Ahmed Bennis: DOACs Increase 1-Year Stroke Risk but Reduce MI Risk Compared With Warfarin
-
Aug 15, 2026, 19:24Megan Adediran: An Unwavering Fight for People Living With Haemophilia
-
Aug 15, 2026, 19:23Intravenous Anticoagulation Linked to Worse Early Outcomes After Noncardioembolic Stroke – International Journal of Stroke
-
Aug 15, 2026, 18:03Alejandro González Veliz: Pulmonary Embolism Is Not Always an Anticoagulation-Only Problem
-
Aug 15, 2026, 17:57Ayesha Zia: A New Foundation for Pediatric Pulmonary Embolism Research and Care
-
Aug 15, 2026, 17:50Muhammad Shaheer Bin Faheem: 25 Years of Thromboembolism and Hypertension Mortality
-
Aug 15, 2026, 17:21Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis